Stocklytics Platform
Asset logo for symbol INBX
Inhibrx
INBX55
$14.49arrow_drop_down1.69%-$0.24
Asset logo for symbol INBX
INBX55

$14.49

arrow_drop_down1.69%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Inhibrx (INBX) Stocklytics Forecast

Inhibrx, Inc., also known as INBX, is a biotechnology company that focuses on the development and commercialization of innovative therapeutics for the treatment of cancer and other diseases. The company's primary goal is to improve the lives of patients by creating novel therapies that target specific proteins involved in disease processes. With a strong pipeline of product candidates, INBX is poised for significant growth in the coming years.
When it comes to predicting the stock price of Inhibrx, Inc., it's important to consider various factors. One approach is to analyze past performance and trends in the biotechnology industry. By evaluating the company's financials and comparing them with industry benchmarks, investors can gain insight into the potential future performance of INBX stock.
add Inhibrx to watchlist

Keep an eye on Inhibrx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Inhibrx (INBX) stock?

Analysts have set a target price of $42.73 for Inhibrx (INBX), based on forecasts from 11 analysts. The predicted price range extends from a high of $60 to a low of $27. This represents a potential increase of up to 314.08% and a decrease of 86.34% from the current price of $14.49. These forecasts are as of 2020 Sep 14.
help

What are the analyst ratings for Inhibrx (INBX) stock?

Currently, there are no analyst ratings available for Inhibrx (INBX), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Inhibrx (INBX) stock?

At present, there is no AI or machine-learning-based price prediction available for Inhibrx (INBX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level